Tailoring sickle cell drug doses: a new hope for nigerian patients

NCT ID NCT07543289

Not yet recruiting Knowledge-focused Sponsor: Ochuko Orherhe Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how genetic differences affect the way Nigerian sickle cell patients respond to hydroxyurea, a common treatment. Researchers will monitor 100 patients to build a computer model that predicts the best dose for each person. The goal is to reduce side effects and improve outcomes like fewer pain crises.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Hydroxyurea
What this could lead to: If successful, this could lead to personalized hydroxyurea dosing guidelines for Nigerian sickle cell patients, making treatment safer and more effective.
What could go wrong: This is an early-stage observational study with only 100 participants, so results may not apply to all patients. The models need further validation before clinical use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sickle cell disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SICKLE CELL DISEASE

Contacts and locations

Locations

Obafemi Awolowo University Teaching Hospital Complex

Ile-Ife, Osun State, 220282, Nigeria

More trials for these conditions

Other studies related to the condition(s) this trial covers.